Jefferies Enhances Equity Research Platform with Addition of Senior Biotechnology Analyst

NEW YORK--(Business Wire)--
In an expansion of the firm`s established healthcare research franchise,
Jefferies announced today the addition of Andrew Fein as a Managing Director and
Senior Equity Research Analyst covering Biotechnology companies. Mr. Fein has
more than ten years of experience as an analyst following the Biotechnology
industry.

The hiring of Mr. Fein extends Jefferies` established coverage of Biotechnology,
which includes senior analysts Thomas Wei and Eun Yang, Ph.D. in the US, and
Peter Welford, CFA, Philippa Gardner, Eng.D. Tara Shivarattan, Ph.D. and James
Vane-Tempest in Europe. Jefferies` Healthcare research team, one of the largest
in the world, is comprised of 20 analysts globally, covering Biotechnology,
Pharmaceuticals, Specialty Pharmaceuticals, Contract Research Organizations
(CROs), Medical Devices, Medical Diagnostics, Life Sciences Tools, Healthcare
Supplies, Healthcare Information Technology, Medical Technology, as well as
Healthcare Services, Facilities and REITs.

"Andrew Fein is a highly-regarded research analyst with strong relationships and
a successful track record of covering Biotechnology companies," commented Steven
R. Black, Global Head of Equity Research at Jefferies. "His experience and
sector expertise will further extend our existing Healthcare research franchise
and add immediate value to our comprehensive equity offering to institutional
investors."

Jefferies` research analysts consistently rank among the top industry
professionals, capturing 23 analyst awards in 2009, including honors from The
Wall Street Journal "Best on the Street" Analyst Survey, Institutional Investor
and Financial Times/StarMine. Jefferies and its affiliates have nearly 175
equity and leveraged finance research professionals in the US and Europe
covering over 1,300 companies in the areas of aerospace & defense, clean
technology, consumer, energy, financial services, gaming & leisure, healthcare,
industrials, maritime, media & entertainment, technology, telecommunications and
utilities.

Mr. Fein was most recently at Piper Jaffray, where he was a Managing Director
covering Biotechnology companies. Previously, he was a Managing Director
covering Biotechnology companies at Collins Stewart (formerly C.E. Unterberg,
Towbin) and held similar roles at Leerink Swann, J.P. Morgan and Deutsche Bank.
He received a BA in Biology and History from Yale University.

Jefferies, a major global securities and investment banking firm, has served
companies and their investors for more than 45 years. Jefferies & Company, Inc.
is the principal operating subsidiary of Jefferies Group, Inc. (NYSE: JEF:
jefferies.com).

Jefferies & Company, Inc.
Tom Tarrant, 203-708-5989
ttarrant@jefferies.com
or
Jefferies International Ltd
Desiree Maghoo, 44 20 7029 8085
dmaghoo@jefferies.com
or
CJP Communications
Josh Passman, 212-279-3115, x203
jpassman@cjpcom.com

Copyright Business Wire 2010